In today’s political climate, it sometimes feels like we can’t even agree on basic facts. We bombard each other with statistics and figures, hoping that more data will make a difference. A progressive person might show you the same climate change graphs over and over while a conservative person might point to the trillions of dollars of growing national debt. We’re left wondering, “Why can’t they just see? It’s so obvious!”

      Certain myths are so pervasive that no matter how many experts disprove them, they only seem to grow in popularity. There’s no shortage of serious studies showing no link between autism and vaccines, for example, but these are no match for an emotional appeal to parents worried for their young children.

      Tali Sharot, a cognitive neuroscientist at University College London, studies how our minds work and how we process new information. In her upcoming book, The Influential Mind, she explores why we ignore facts and how we can get people to actually listen to the truth. Tali shows that we’re open to new information – but only if it confirms our existing beliefs. We find ways to ignore facts that challenge our ideals. And as neuroscientist Bahador Bahrami and colleagues have found, we weigh all opinions as equally valid, regardless of expertise.

      So, having the data on your side is not always enough. For better or for worse, Sharot says, emotions may be the key to changing minds.

                                          (Shankar Vedantam. www.npr.org. Adaptado.)

Opportunity Cost

This phenomenon goes by the name of ‘opportunity cost,’ since by not investing in more equipment and a more rigid production flow, the company is forgoing the opportunity to earn increased profits. These costs are every bite as real as the payment of dollars out-of-pocket.

This notion _______ opportunity cost can be reinforced _________ a famous saying ______ Benjamin Franklin, no slouch himself _________ operations management. To make the point, however, we must make a brief excursion into logic. One truth of logic is the validity of the so-called contrapositive, which says simply that if the statement “If A, then B” is true, then it is also true that “If not B, then not A.” That is, of every time A occurs B follows, then we can be sure that if B does not occur, then A did not occur as well. Enough logic then, and back to Ben Franklin.

One of his Poor Richard sayings is that “A penny saved is a penny earned.” We have all recognized the truth of that since childhood, but I assert that by this saying Ben showed us he knows everything about opportunity cost. After all, what is the contrapositive of “A penny not earned is a penny not saved (i.e., a penny sent). All we are saying by this notion of opportunity cost is that “a penny not earned (an opportunity forgone) is a penny spent.” We shall often have occasion to consider opportunity costs, in analyzing and deciding various operations issues.

SCHMENNER, Roger W. Production/Operations Management. 5th Edition. Prentice-Hall, 1993.

Text

A French art expert believes a charcoal drawing kept in a collection for more than 150 years may be a preparatory sketch made by Leonardo da Vinci of the Mona Lisa.

The black-and-white drawing of a woman, nude from the waist up, known as the Monna Vanna, was previously attributed to Leonardo’s studio, suggesting it was done in his style by a pupil or follower, not by the master himself.

But after preliminary tests at the Louvre Museum, experts believe the sketch may well have been drawn by Leonardo.

Among the signs, according to curator Mathieu Deldicque, are the fact the drawing was made during the same period as the Mona Lisa, the paper is from the same region of Italy, and the technique is very similar to that of the Mona Lisa.

“We know the drawing was made during the lifetime of Leonardo da Vinci, we know that the paper was made in Italy, between Venice and Florence, and the third discovery is the high quality of this drawing in the face of the Monna Vanna and in her arms,” Deldicque told reporters.

“That’s very interesting because the arms are the same as the Mona Lisa‘s.”

Leonardo, who lived from 1452 to 1519, was an engineer, scientist, inventor and sculptor, as well as one of the finest artists of the Italian Renaissance.

He painted the Mona Lisa, also known as La Gioconda and regarded as the world’s most valuable artwork, at the beginning of the 16th century. It is believed to depict Lisa Gherardini, the wife of a successful merchant.

EXCITING

The charcoal portrait, in which the woman is holding a similar pose to the Mona Lisa but with her body more side-on and her head turned further over her left shoulder, has been held in a collection at the Conde Museum at the Palace of Chantilly, north of Paris, since 1862.

The Mona Lisa and Monna Vanna hold their hands in very similar ways, the right hand across the left and resting on the forearm, the fingers gently extended.

Deldicque said that while it was exciting to think the charcoal drawing was created by Leonardo, there were more tests to be done.

“We have one more month of analysis and then a very slow process of history of art with a collection of analysts and advice by specialists,” he said. 

It is possible that process will determine that the authorship is the same. But it may also be inconclusive, he said, adding:

“Maybe the mystery will remain.”

(Source: adapted from http://www.reuters.com/article/us-france-monalisa-sketch/is-16th-century-charcoal-sketch-a-naked-mona-lisa-idUSKCN1C42LD, retrieved on October 1, 2017) 

Re-Planting a Forest, One Drone at a Time

That funny little buzz you hear in the forest may not just be the hum of summer insects. In the near future it could be a small fleet of drones, coming to replant and restore forests that have been stripped of trees by industrial-scale deforestation. It’s all part of an ambitious plan by BioCarbon Engineering, a U.K.-based startup on a global mission to battle widespread clear-cutting, which strips more than 26 billion trees off the planet each year. CEO Lauren Fletcher, who spent 20 years as an engineer with NASA, says the only way to fight industrial-scale deforestation is with industrial-scale reforestation. Their idea: plant 1 billion trees a year. The first targets are in South Africa and the Amazonian jungles, both of which have suffered from widespread forest eradication.

BioCarbon’s reforestation scheme is simple and efficient. Here’s a quick look at how it plans to deploy its drone fleet: 

1 Do a 3-D aerial survey. First, drones are sent to fly over a potential planting zone, snapping photos that create 3-D maps of the area to be reforested. The number of drones will vary depending up on the size of the seeding.

2 Create a seeding plan. Once all that terrain data has been analyzed, it then generates a seeding pattern that best suits the terrain.

3 Load the seed pods. The drones, which are equipped with guidance and control software, carry pressurized canisters of seed pods with germinated seeds immersed in a nutrient-rich gel.

4 Hover and plant. Flying at a height of 1 or 2 meters, the drones follow the planting patterns, firing the biodegradable seed pods down to the ground. The pods break open upon impact, allowing the germinated seed a chance to take root.

5 Monitor growth. After planting, the drones do low-level flights to assess the health of the sprouts and saplings.

Such “precision forestry,” as BioCarbon calls it, is extremely efficient. A farmer might hand plant as many as 3,000 seeds a day; Fletcher says his drones can drop up to 36,000 seed pods daily, often in areas where a human can’t reach. Working with local ecologists, BioCarbon will use the drones to spread a variety of tree species, as well as microorganisms and fungi designed to improve the soil quality. “The central focus is ecosystem restoration,” Fletcher says.

On a planetary climatological scale, Morton notes that “tropical deforestation plays a big role in global climate cycles,” claiming the accelerated pace of cutting and burning of forests accounted for 20 percent of greenhouse gas emissions in the 1990s. Fletcher and his team want to help reverse that trend. “By planting at the scale we’re looking at,” he says, “we can make a real longterm impact. We hope to do a lot of good in the world.”

(Adapted from https://www.wired.com/brandlab/2015/07/re-planting-forest-one-drone-time/. Access on 22/8/2017)

TEXTO

Brazil has declared an end to its public health emergency over the Zika virus, 18 months after a surge in cases drew headlines around the world.

The mosquito-borne virus was not considered a major health threat until the 2015 outbreak revealed that Zika can lead to severe birth defects. One of those defects, microcephaly, causes babies to be born with skulls much smaller than expected.

Photos of babies with the defect spread panic around the globe as the virus was reported in dozens of countries. Many would-be travellers cancelled their trips to Zika-infected places. The concern spread even more widely when health officials said it could also be transmitted through sexual contact with an infected person.

The health scare came just as Brazil, the epicentre of the outbreak, was preparing to host the 2016 Olympics, fuelling concerns the Games could help spread the virus. One athlete, a Spanish wind surfer, said she got Zika while training in Brazil ahead of the Games.

In response to the outbreak, Brazil launched a mosquito-eradication campaign. The health ministry said those efforts have helped to dramatically reduce cases of Zika. Between January and mid-April, 95% fewer cases were recorded than during the same period last year. The incidence of microcephaly has fallen as well. 

The World Health Organization (WHO) lifted its own international emergency in November, even while saying the virus remained a threat. 

“The end of the emergency doesn’t mean the end of surveillance or assistance” to affected families, said Adeilson Cavalcante, the secretary for health surveillance at Brazil’s health ministry. “The health ministry and other organisations involved in this area will maintain a policy of fighting Zika, dengue and chikungunya.”

All three diseases are carried by the Aedes aegypti mosquito.

But the WHO has warned that Zika is “here to stay,” even when cases of it fall off, and that fighting the disease will be an ongoing battle.

(Fonte: Associated Press, Friday 12 May 2017 10.18 BST. Last modified on Friday 12 May 2017 22.00 BST) 

Read TEXT 1 below and answer question

TEXT 1

World Health Officials Describe Progress Against Tetanus, H.I.V. and Malaria

    Infant and maternal tetanus was officially eliminated from the Americas this year, the Pan American Health Organization announced on Thursday. At one time, the infection killed about 10,000 newborns annually in the Western Hemisphere; tetanus still kills about 35,000 infants around the world. It was one of several significant global health advances, including new programs against malaria and H.I.V., announced last week in conjunction with the meeting of the United Nations General Assembly in New York.
    Haiti was the last country in the Americas to eliminate neonatal tetanus. That does not mean complete eradication, because the bacteria that cause tetanus exist everywhere in soil and animal droppings. Rather, elimination means that thanks to vaccination of mothers and clean birth procedures — less than one case occurs per 1,000 live births.
    The Americas have generally led the world in eliminating diseases for which vaccines exist. In this hemisphere, smallpox was eliminated in 1971, polio in 1994, rubella in 2015 and measles in 2016 (the diseases are sometimes reintroduced, as measles was at Disneyland in 2014, but outbreaks are usually brought quickly under control).
    Also this week, the President’s Malaria Initiative said it would expand its work to new countries in West and Central Africa, protecting 90 million more people. The initiative, founded in 2005 as part of the United States Agency for International Development, has been a major force in driving down worldwide malaria deaths by about 40 percent in the past decade. The disease most often kills young children and pregnant women. The expansion in Cameroon, Ivory Coast, Niger, Sierra Leone and Burkina Faso was made possible because Congress increased funding for the initiative in fiscal year 2017, a representativ said
    In his speech to the United Nations on Tuesday, President Trump praised the malaria initiative and the President’s Emergency Plan for AIDS Relief as examples of leadership in humanitarian assistance by the United States.
    A combination of aid agencies, drug companies and g cocktail to treat H.I.V. would soon be available to 92 countries, including virtually all of Africa, for about $75 a year. The new AIDS cocktail is the first available in poor countries to contain dolutegravir, which is widely used in wealthy countries because it is highly effective and has few side effects. The pill also contains lamivudine, an older but still effective drug, and tenof disoproxil fumarate, another modern drug whose inclus effects and resistance.
    Almost 37 million people in the world have H.I.V., according to Unaids, the U.N.’s AIDS-fighting agency, but fewer than 20 million are now on antiretroviral medicine, which not only saves their lives but prevents them from passing on the disease.

McNEIL Jr., Donald. Disponível em: < https://www.nytimes.com/2017/09/22/health/world-health-tetanus-infants.html?mcubz=1>. Acesso em: 22/09/2017. 

Text1

Autism's Drug Problem 

Many people on the spectrum take multiple medications, which can lead to serious side effects and may not even be effective

Connor was diagnosed with autism early — when he was just 18 months old. His condition was already obvious by then. “He was lining things up, switching lights on and off, on and off,” says his mother, Melissa. He was bright, but he didn’t speak much until age 3, and he was easily frustrated. Once he started school, he couldn’t sit still in class, called out answers without raising his hand and got visibly upset when he couldn’t master a math concept or a handwriting task quickly enough. “One time, he rolled himself up into the carpet like a burrito and wouldn’t come out until I got there,” Melissa recalls. (All families in this story are identified by first name only, to protect their privacy.) 
Connor was prescribed his first psychiatric drug, methylphenidate (Ritalin), at age 6. That didn’t last long, but when he was 7, his parents tried again. A psychiatrist suggested a low dose of amphetamine and dextroamphetamine (Adderall), a stimulant commonly used to treat attention deficit hyperactivity disorder (ADHD). The drug seemed to improve his time at school: He was able to sit still for longer periods of time and focus on what his teachers were saying. His chicken-scratch handwriting became legible. Then, it became neat. Then perfect. And then it became something Connor began to obsess over.
“We were told that these are the gives and takes; if it’s helping him enough to get through school, you have to decide if it’s worth it,” Melissa says. It was worth it — for a while.  
But when the Adderall wore off each day, Connor had a tougher time than ever. He spent afternoons crying and refusing to do much of anything. The stimulant made it difficult for him to fall asleep at night. So after a month or two, his psychiatrist added a second medication — guanfacine (Intuniv), which is commonly prescribed for ADHD, anxiety and hypertension, but can also help with insomnia. The psychiatrist hoped it might both ease Connor’s afternoons and help him sleep. 
In some ways, it had the opposite effect. His afternoons did get slightly better, but Connor developed intense mood swings and was so irritable that every evening was a struggle. Rather than simply tossing and turning in bed, he refused to even get under the covers. “He wouldn’t go to bed because he was always angry about something,” Melissa says. “He was getting himself all wound up, carrying on, getting upset at night and crying.” 
 wound up, carrying on, getting upset at night and crying.” After seven months, his parents declared the combination unsustainable. They swapped guanfacine for over-the-counter melatonin, which helped Connor fall asleep with no noticeable side effects. But within a year, he had acquired a tolerance for Adderall. Connor’s psychiatrist increased his dosage and that, in turn, triggered tics: Connor began jerking his head and snorting. Finally, at his 9-year physical, his doctor discovered that he’d only grown a few inches since age 7. He also hadn’t gained any weight in two years; he’d dropped from the 50th percentile in weight to the 5th. That was the end of all the experiments. His parents took him off all prescription drugs, and today, at almost 13 years old, Connor is still medication-free. His tics have mostly disappeared. Although he has trouble maintaining focus in class, his mother says that the risk-benefit ratio of trying another drug doesn’t seem worth it. “Right now we’re able to handle life without it, so we do.”
(...)
For Connor, eliminating prescription drugs was difficult, but doable. For others, multiple medications may seem indispensable. It’s not unusual for children with autism to take two, three, even four medications at once. Many adults with the condition do so, too. Data are scant in both populations, but what little information there is suggests multiple prescriptions are even more common among adults with autism than in children. Clinicians are particularly concerned about children with the condition because psychiatric medications can have long-lasting effects on their developing brains, and yet are rarely tested in children. 
In general, polypharmacy — most often defined as taking more than one prescription medication at once — is commonplace in people with autism. In one study of more than 33,000 people under age 21 with the condition, at least 35 percent had taken two psychotropic medications simultaneously; 15 percent had taken three.
“Psychotropic medications are used pretty extensively in people with autism because there aren’t a lot of treatments available,” says Lisa Croen, director of the Autism Research Program at Kaiser Permanente in Oakland, California. “Is heavy drug use bad? That’s the question. We don’t know; it hasn’t been studied.”

  Disponível em: <https://www.scientificamerican.com/article/autisms-drug-problem/>. Texto adaptado. 

Read the text below and answer the following questions based on it.

In 2017 the protestant church is celebrating an important event: the 500th anniversary of the Reformation